Effect of oestrous synchronization with estradiol 17beta and progesterone on follicular wave dynamics in dairy heifers.
An experiment was designed to evaluate the effects of estradiol-17beta (E17beta) on follicular wave dynamics and ovulatory response in Holstein heifers receiving either a progestogen ear-implant (Crestar; Intervet International b.v. Boxmeer, The Netherlands) or an intravaginal progesterone-releasing device [controlled internal drug release-bovine device (Eazibreed, CIDR-B; Bodinco BV, Alkmaar, The Netherlands)]. For comparison, another group of heifers was also synchronized using Crestar plus an injection of estradiol valerate (EV) and norgestomet as recommended by the pharmaceutical company. Twenty 20-22-month-old cycling Holstein heifers were allocated to one of the following treatment groups at random stages of the oestrous cycle: (I) simultaneous insertion of Crestar and intramuscular injection of 3 mg norgestomet and 5 mg EV (Crestar 9 + EV 9); (II) simultaneous insertion of Crestar and intramuscular injection of 5 mg E17beta (Crestar 9 + E17beta 9); (III) insertion of Crestar followed 2 days later by intramuscular injection of 5 mg E17beta (Crestar 9 + E17beta 7); or (IV) insertion of CIDR-B device followed 2 days later by intramuscular injection of 5 mg E17beta (CIDR 9 + E17beta 7). The CIDR-B or Crestar implants were removed after 9 days and all heifers received 500 microg Cloprostenol (Estrumate, Pitman-Moore Nederland BV, Houten. The Netherlands). Ovarian ultrasonographic examinations were performed once daily during the synchronization period using a B-mode scanner equipped with a 7.5 MHz linear-array transrectal transducer. In addition, heifers were scanned every 12 h after implant/device withdrawal until 3 days after ovulation in order to monitor follicular activity, detect ovulation and subsequent early luteal formation. Detection of oestrus was performed every 6 h for 4 days after device/implant removal. Oestrus was observed 24-32 h before ovulation in all heifers. The mean hours interval from treatment withdrawal to ovulation was not significantly different (84.0 +/- 16.5, 77.6 +/- 4.1, 73.6 +/- 4.1 and 64.0 +/- 4.4 h for treatments I, II, III and IV, respectively, p > 0.1). However, the variance for heifers treated with EV + norgestomet was significantly larger (Levene's Test; p < 0.01) than those treated with E17beta. All E17beta treatments resulted in dominant follicle suppression and a new wave emerged 4.1 days after treatment compared with 6.6 days for the EV + norgestomet treatment (p < 0.05). The time from emergence of the new ovulatory wave to ovulation was longer for the new wave that emerged after E17beta treatment (9.2 +/- 0.3 days) than after EV + norgestomet treatment (6.9 +/- 0.4 days; p < 0.05). The results of this study suggest that the four treatments used were effective in inducing synchronous behavioural oestrus and ovulation. However, a higher degree of oestrus and ovulation synchrony was observed in heifers treated with E17beta than in heifers treated with EV + norgestomet. Synchronization treatments with exogenous E17beta or EV + norgestomet at the time of progestin device insertion (Crestar or CIDR-B) or 2 days later in heifers can regulate a different emergence pattern of ovarian follicular development in randomly cyclic heifers. The E17beta was effective in inducing follicular suppression and resulted in the consistent emergence of a new follicular wave.
Garcia
A
A
Pharming B.V., Polsbroek, The Netherlands.
Salaheddine
M
M
D000282:Administration, Intravaginal; D000818:Animals; D002417:Cattle / Q000502:physiology*; D003692:Delayed-Action Preparations; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D004972:Estrus Detection; D004973:Estrus Synchronization / Q000379:methods*; D005260:Female; D007273:Injections, Intramuscular / Q000662:veterinary; D006080:Ovarian Follicle / Q000187:drug effects* / Q000502:physiology; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology; D011897:Random Allocation
D003692:Delayed-Action Preparations; D004343:Drug Implants; D011282:Pregnenediones; D045167:Progesterone Congeners; C100284:norgestomet; D011374:Progesterone; D004958:Estradiol